Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» J&J's Invokana lowers CV risk, but by enough to compete?
J&J's Invokana lowers CV risk, but by enough to compete?
J&J's Invokana lowers CV risk, but by enough to compete?
Submitted by
admin
on June 14, 2017 - 11:37am
Source:
BioPharma Dive
News Tags:
JNJ
Invokana
diabetes
Jardiance
Eli Lilly
Boehringer Ingelheim
Headline:
J&J's Invokana lowers CV risk, but by enough to compete?
Do Not Allow Advertisers to Use My Personal information
